🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Steven Cohen’s SMMT Holdings & Trades

First Buy
Q1 2026
Duration Held
1 Quarters
Largest Add
Q1 2026
+784,186 Shares
Current Position
784,186 Shares
$14.87 M Value

Steven Cohen's SMMT Position Overview

Steven Cohen (via Point72 Asset Management, L.P.) currently holds 784,186 shares of Summit Therapeutics Inc. (SMMT) worth $14.87 M, representing 0.02% of the portfolio. First purchased in 2026-Q1, this recently established position has been held for 1 quarters.

Based on recent 13F filings, Steven Cohen has initiated a new position in SMMT, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.

Analysis based on 13F filings available since 2013 Q2

Steven Cohen's Summit Therapeutics (SMMT) Holding Value Over Time

Track share changes against reported price movement

Quarterly Summit Therapeutics (SMMT) Trades by Steven Cohen

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q1 2026 +784,186 New Buy 784,186 $18.96

Steven Cohen's Summit Therapeutics Investment FAQs

Steven Cohen first purchased Summit Therapeutics Inc. (SMMT) in Q1 2026, acquiring 784,186 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Steven Cohen has held Summit Therapeutics Inc. (SMMT) for 1 quarters since Q1 2026.

Steven Cohen's largest addition to Summit Therapeutics Inc. (SMMT) was in Q1 2026, adding 784,186 shares worth $14.87 M.

According to the latest 13F filing for Q1 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 784,186 shares of Summit Therapeutics Inc. (SMMT), valued at approximately $14.87 M.

As of the Q1 2026 filing, Summit Therapeutics Inc. (SMMT) represents approximately 0.02% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.

Steven Cohen's peak holding in Summit Therapeutics Inc. (SMMT) was 784,186 shares, as reported at the end of Q1 2026.